Korro Bio (KRRO) Non-Current Deffered Revenue (2019 - 2026)
Korro Bio's (KRRO) quarterly Non-Current Deffered Revenue came in at $7.7 million in Q1 2026, up 26.59% YoY from $6.0 million in Q1 2025, and down 2.28% on a QoQ basis from $7.8 million in Q4 2025.
Korro Bio (KRRO) Non-Current Deffered Revenue (2019 - 2026) Analysis & Trends
Korro Bio (KRRO) has 5 years of Non-Current Deffered Revenue data on file, last reported at $7.7 million in Q1 2026.
- Quarterly Non-Current Deffered Revenue rose 26.59% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (up 26.59% YoY) and the FY2025 annual result came in at $7.8 million, up 32.53% from the prior year.
- Non-Current Deffered Revenue retreated to $7.7 million in Q1 2026, from $7.8 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $7.8 million in Q4 2025 to a low of $4.5 million in Q2 2025.
- A 3-year average of $6.4 million and a median of $6.0 million in 2025 frame the typical range for Non-Current Deffered Revenue.
- The widest YoY moves for Non-Current Deffered Revenue: up 32.53% in 2025, down 38.45% in 2025.
- Tracing KRRO's Non-Current Deffered Revenue over 3 years: stood at $5.9 million in 2024, then jumped by 32.53% to $7.8 million in 2025, then declined by 2.28% to $7.7 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $7.7 million (Q1 2026), $7.8 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | 6.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.81 Mn |
| Mar 31, 2026 | 7.66 Mn |
| Dec 31, 2025 | 7.84 Mn |
| Sep 30, 2025 | 4.80 Mn |
| Jun 30, 2025 | 4.50 Mn |
| Mar 31, 2025 | 6.05 Mn |
| Dec 31, 2024 | 5.91 Mn |
| Sep 30, 2024 | 7.80 Mn |
| Mar 31, 2020 | 5.11 Mn |
| Dec 31, 2019 | 2.90 Mn |
| Sep 30, 2019 | 6.40 Mn |